Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from MEDIROM Healthcare Technologies ( (MRM) ) is now available.
The company refinanced part of its December 2022 convertible bond issuance by closing a new ¥275 million fourth unsecured convertible bond with share options on December 31, 2025, allowing Kufu Company Holdings to roll over maturing debt at a 5% coupon with conversion rights through June 2026. On January 30, 2026, MEDIROM further restructured ¥200 million of the prior bonds into a short-term 10% loan secured by all shares of subsidiary MEDIROM MOTHER Labs, while repaying the remaining ¥25 million in cash, underscoring tighter liquidity management and heightened collateralization with implications for governance and creditor control if covenants are breached.
The most recent analyst rating on (MRM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.
Spark’s Take on MRM Stock
According to Spark, TipRanks’ AI Analyst, MRM is a Neutral.
The overall stock score is primarily influenced by financial performance and technical analysis. While the company shows strong revenue growth, profitability and liquidity challenges are significant concerns. The technical indicators suggest a bearish trend, but the stock appears undervalued based on its P/E ratio.
To see Spark’s full report on MRM stock, click here.
More about MEDIROM Healthcare Technologies
MEDIROM Healthcare Technologies is a Japan-based wellness services operator focused on relaxation salons and digital health solutions for lifestyle-related conditions in the domestic market.
Average Trading Volume: 108,779
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.54M
Learn more about MRM stock on TipRanks’ Stock Analysis page.